Human microbiome, also known as microbiota is made up of trillions of microbes like fungi, bacteria, archaea, and others, which dwell on human body parts like the surface or in deep layers of skin. When their number grows beyond the stipulated range, normal physiological functions get disturbed, thus giving rise to diseases. Rising cases of various diseases due to unhealthy lifestyle, increasing cases of autoimmune disorders, and rising applications in therapeutics and diagnostics segments is likely to stimulate the growth of human microbiome market.
Drivers & Restraints
The growth of the global market for human microbiome can be primarily attributed to the following factors:
- Rising aging population
- Developments in technology such as microbiome sequencing
- Increasing cases of lifestyle diseases
- Demand for efficient and safe medication with no side effects
- Need for early detection and diagnosis has led to the increased use of microbiomes in molecular diagnostics
Moreover, leading companies in this market are adopting strategies like joint ventures, collaborations & partnerships, etc., which is further boosting the growth of this market. However, government regulations, lack of comprehensive research, and lack of knowledge among masses regarding the efficient usage and effects of prebiotics and probiotics may hamper the growth of this market.
Market at a Glance
The worldwide human microbiome market which is estimated to be valued at USD 294 Million in 2019 is expected to reach USD 658 Million by 2023, growing at a CAGR of 22.3% during the forecast period (2019–2023). Geographically, Europe is expected to hold the largest market share over the forecast period due to the increasing acceptance of probiotic and prebiotic products. Asia-Pacific is expected to offer potential growth opportunities and is expected to advance at a healthy CAGR, whereas the North American market is likely to grow at a high CAGR between 2019 and 2023.
Among applications, therapeutics segment holds the largest market share, owing to rising population and diseases. Based on product, probiotics is estimated to hold the largest market and grow at a CAGR of 25.2% over the forecast period. On the basis of technology, the cell culture technology took up the largest share of the market in 2015.
Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.) are the major players involved in the global market for human microbiome.
Ask for PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=37621904
Research Scope
The global market for human microbiome has been analyzed and forecasted on the basis of following segmentation:
- Product: Probiotics, Prebiotics, Food, Medical Foods, Devices, Drugs, Other Probiotic Supplements
- Application: Therapeutics, Diagnostics
- Disease: Obesity, Diabetes, Autoimmune Disorder, Cancer, Acute Diarrhea, Mental Disorder, Others
- Product Research: Instruments, Consumables
- Technology: Omics Technology, High-throughput Technology, Cell Culture Technology, Computational Tools
- Geography: North America, Europe, Asia-Pacific, RoW
